Galapagos NV Share Price

Equities

GLPG

BE0003818359

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam 16:35:26 18/06/2024 BST After market 20:28:50
24.02 EUR +0.59% Intraday chart for Galapagos NV 24.09 +0.29%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 296M 318M 25.04B Sales 2025 * 302M 324M 25.53B Capitalization 1.58B 1.7B 134B
Net income 2024 * -22M -23.62M -1.86B Net income 2025 * -72M -77.31M -6.08B EV / Sales 2024 * -6.02 x
Net cash position 2024 * 3.37B 3.62B 285B Net cash position 2025 * 2.97B 3.19B 251B EV / Sales 2025 * -4.6 x
P/E ratio 2024 *
-40 x
P/E ratio 2025 *
-15 x
Employees 1,123
Yield 2024 *
-
Yield 2025 *
-
Free-Float 74.64%
More Fundamentals * Assessed data
Dynamic Chart
Galapagos Plans to Present 'Encouraging' Results for GLPG5101 in Non-Hodgkin Lymphoma MT
Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment MT
Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug MT
Galapagos and Adaptimmune Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-Cell Therapy Candidate, uza-cel CI
Galapagos Partners with Blood Centers of America to Decentralize CAR-T Cell Therapy Manufacture MT
Galapagos and Blood Centers of America Announce Strategic Collaboration to Accelerate Galapagos? Decentralized Car-T Manufacturing Network in the U.S CI
Transcript : Galapagos NV, Q1 2024 Earnings Call, May 03, 2024
Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024 CI
Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says MT
BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41 MT
Galapagos NV Announces Board Changes CI
Galapagos to Seek Acquisitions CI
Transcript : Galapagos NV, 2023 Earnings Call, Feb 23, 2024
Frontier Medicines Corporation announced that it has received $80.000001 million in funding from Deerfield Management Company, L.P. Series C, DROIA nv, Galapagos NV, DCVC, MPM Asset Management, L.L.C., RA Capital Management, L.P. and other investors CI
More news
1 day+0.59%
1 week-1.56%
Current month-6.68%
1 month-10.97%
3 months-22.49%
6 months-33.39%
Current year-35.06%
More quotes
1 week
23.64
Extreme 23.64
25.86
1 month
23.64
Extreme 23.64
27.50
Current year
23.64
Extreme 23.64
39.00
1 year
23.64
Extreme 23.64
40.26
3 years
23.64
Extreme 23.64
66.28
5 years
23.64
Extreme 23.64
252.90
10 years
10.00
Extreme 10
252.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 31/03/22
Director of Finance/CFO 54 31/05/23
Investor Relations Contact - 31/10/20
Members of the board TitleAgeSince
Director/Board Member 54 03-26
Director/Board Member 66 25/04/22
Director/Board Member 65 18/09/23
More insiders
Date Price Change Volume
18/06/24 24.02 +0.59% 107 768
17/06/24 23.88 +0.34% 343,427
14/06/24 23.8 -0.42% 68,527
13/06/24 23.9 -0.42% 100,189
12/06/24 24 -1.64% 117,733

Real-time Euronext Amsterdam, June 18, 2024 at 04:35 pm

More quotes
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
23.88 EUR
Average target price
36.73 EUR
Spread / Average Target
+53.81%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW